Publication | Open Access

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Breast OncologyMedicinePharmacologyPathologyPhase Ii StudyTrastuzumab-based TherapyBreast CancerCancer TreatmentOncologyRadiation Oncology